UEGweek 2022
Is IL-23 the super target?
high5immunology.tv | IBD | UEG Week 2022
UEGweek 2022
Is IL-23 the super target?
LADI
UEGweek 2022
What is the best dose of adalimumab in CD?
VEGA, REACT-2
UEGweek 2022
What is new in anti-TNFα therapy?
STARDUST
UEGweek 2022
Treat-to-target with ustekinumab - why didn't it work?
LOVE-CD
UEGweek 2022
The benefit of early intervention in CD
REACT-2
UEGweek 2022
Treat-to-target still alive?
LADI
UEGweek 2022
Personalized therapy - de-escalation strategies
LATTICE-UC
UEGweek 2022
TYK2 Deucravacitinib in ulcerative colitis
VEGA
UEGweek 2022
Combination therapy: week 38 efficacy and safety data…
UEGweek 2022
Postoperative monitoring matters!
VEGA
UEGweek 2022
Longterm potential benefit of a combIo therapy
UEGweek 2022
Anti-IL-23 monoclonal antibodies: is it better to…
LOVE-CD
UEGweek 2022
Once more a shocking message: be aware of steroids!
VEGA
UEGweek 2022
VEGA - the story continues
UEGweek 2022
No matter what you use - treat early!
REACT-2
UEGweek 2022
Enhanced treatment algorithm for the management of CD
REACT-2
UEGweek 2022
Treat-to-target strategy is superior to conventional…
UEGweek 2022
T reg - a new therapeutic target in IBD?
UEGweek 2022
Treating the patient as a whole
STARDUST
UEGweek 2022
Pharmacokinetics of ustekinumab in the STARDUST trial
UEGweek 2022
Small molecules in crohn's disease
IDEAL
UEGweek 2022
Oral anti-integrin therapy in IBD - new data, new…
UEGweek 2022
You can still treat severe biofailure in CD
UEGweek 2022
Explosion of new drugs
UEGweek 2022
Thinking out of the box - co-medication of the elderly
VEGA
UEGweek 2022
VEGA - l'histoire continue
UEGweek 2022
Treating the patient as a whole
UEGweek 2022
Small molecules nel morbo di crohn
UEGweek 2022
Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!
VEGA
UEGweek 2022
Les résultats à long terme d'une combIothérapie
VEGA
UEGweek 2022
Terapia di combinazione: efficacia e sicurezza a 38…
UEGweek 2022
Anticorps anti-IL-23: est-il préferabble de cibler…
UEGweek 2022
Was tun nach der Operation?
REACT-2
UEGweek 2022
Una strategia “Treat-to-target” è superiore rispetto…
IDEAL
UEGweek 2022
Doustna terapia antyintegrynowa - nowe dane, nowe…
UEGweek 2022
T reg - nowy cel terapeutyczny w IBD?
UEGweek 2022
Thinking out of the box - Einfluss der…
UEGweek 2022
Explosión de nuevos fármacos
UEGweek 2022
Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά…
LOVE-CD
UEGweek 2022
Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα…
LATTICE-UC
UEGweek 2022
TYK2 Deucravacitinib bei Colitis ulcerosa
U-ACHIEVE
UEGweek 2022
Update on JAK inhibition in UC
U-EXCEL
UEGweek 2022
1st JAK inhibitor in CD - a game changer?
ELEVATE UC 52, ELEVATE UC 12, TRUE NORTH
UEGweek 2022
S1P receptor modulators
LUCENT-1, LUCENT-2
UEGweek 2022
Update on IL-23 inhibition in UC
LUCENT-1, LUCENT-2
UEGweek 2022
Histological response and remission induced by…
U-EXCEL
UEGweek 2022
The 1st JAKi in CD
UEGweek 2022
Risankizumab in refractory CD patients
TRUE NORTH
UEGweek 2022
Ozanimod works in young and old UC patient
U-EXCEL
UEGweek 2022
Upadacitinib - induction therapy in CD
UEGweek 2022
The era of small molecules
U‑ACHIEVE
UEGweek 2022
Final efficacy and safety results from Upadacitinib 52…
U-ACHIEVE
UEGweek 2022
JAK-inhibition
U-ACHIEVE
UEGweek 2022
Upadacitinib maintenance therapy - final results from…
VEGA, LUCENT-1, LUCENT-2
UEGweek 2022
VEGA & LUCENT studies
ELEVATE UC 52 & 12
UEGweek 2022
Estrasimod in moderate to severe active UC
UEGweek 2022
Persistance on therapy and real-world clinical…
QUASAR, LUCENT-1, LUCENT-2, FORTIFY
UEGweek 2022
Selective IL-23 blockade
U‑ACHIEVE
UEGweek 2022
Risultati finali di efficacia e sicurezza a 52…
UEGweek 2022
Persistenza in terapia ed efficaci clinica di…
UEGweek 2022
The area of small molecules
U-ACHIEVE
UEGweek 2022
JAK-Inhibition
QUASAR, LUCENT-1, LUCENT-2, FORTIFY
UEGweek 2022
Selective IL-23 Blockade
VEGA, LUCENT-1, LUCENT-2
UEGweek 2022
VEGA & LUCENT studi clinici
U-EXCEL
UEGweek 2022
Upadacitinib - Induktionsdaten bei CD
UEGweek 2022
Risankizumab dans la maladie de Crohn réfractaire
UEGweek 2022
Treating the elderly - closer surveillance and the…
OCTAVE
UEGweek 2022
Updated safety data on JAK inhibitors
U-ACHIEVE/U-ACCOMPLISH, LUCENT, CONFIDE
UEGweek 2022
Urgency - putting the focus on an important endpoint!
UK IBD BioResource database
UEGweek 2022
Steroid effects as treatment goals: quality of life and…
CONFIDE
UEGweek 2022
New endpoints in IBD
LUCENT-1, LUCENT-2
UEGweek 2022
Urgency matters!
UEGweek 2022
Patient reported outcomes in IBD
SELECTION
UEGweek 2022
Filgotinib is efficacious in inducing and maintaining…
UEGweek 2022
Patienten gerichtete Endpunkte bei CED
CONFIDE
UEGweek 2022
Neue Studienendpunkte in IBD
SEXEII, BUTTERFLY
UEGweek 2022
Explosion of Spanish contributions
UEGweek 2022
Whats's the origin of Crohn's genetics ? The history of…
UEGweek 2022
Wo kommt die Crohn-Genetik her? Die Historie der IL-23…
UEGweek 2022
Explosión de las comunicaciones españolas
LADI, LUCENT-1, LUCENT-2
UEGweek 2022
Personalised therapy in IBD
LADI, LUCENT-1, LUCENT-2
UEGweek 2022
Individualisierte Therapie bei CED
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!